AstraZeneca PLC (ETR: ZEG)

Market Cap	197.95B
Revenue (ttm)	45.91B
Net Income (ttm)	5.82B
Shares Out	n/a
EPS (ttm)	3.72
PE Ratio	33.99
Forward PE	n/a
Dividend	2.72 (2.11%)
Ex-Dividend Date	Aug 8, 2024

Volume	9,023
Average Volume	23,390
Open	129.65
Previous Close	129.95
Day's Range	128.65 - 130.10
52-Week Range	112.35 - 158.20
Beta	0.18
RSI	51.97
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ZEG

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial numbers in USD